0RB1 Stock Overview
Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Laboratorio Reig Jofre, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.51 |
| 52 Week High | €2.86 |
| 52 Week Low | €2.20 |
| Beta | 0.89 |
| 1 Month Change | -0.40% |
| 3 Month Change | 4.58% |
| 1 Year Change | n/a |
| 3 Year Change | -50.98% |
| 5 Year Change | n/a |
| Change since IPO | -57.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RB1 | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -2.0% | 1.8% | 2.0% |
| 1Y | n/a | 6.6% | 4.5% |
Return vs Industry: Insufficient data to determine how 0RB1 performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 0RB1 performed against the UK Market.
Price Volatility
| 0RB1 volatility | |
|---|---|
| 0RB1 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0RB1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0RB1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 1,331 | Ignasi Reig | www.reigjofre.com |
Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers medical devices, cosmetics, parapharmacy, and animal food related products; and biotechnological and health products. Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, joint health and pain, women’s health, respiratory/ENT, and pediatrics; and consumer healthcare products under the Forté Pharma brand.
Laboratorio Reig Jofre, S.A. Fundamentals Summary
| 0RB1 fundamental statistics | |
|---|---|
| Market cap | €202.51m |
| Earnings (TTM) | €9.41m |
| Revenue (TTM) | €317.95m |
21.5x
P/E Ratio0.6x
P/S RatioIs 0RB1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RB1 income statement (TTM) | |
|---|---|
| Revenue | €317.95m |
| Cost of Revenue | €141.06m |
| Gross Profit | €176.89m |
| Other Expenses | €167.48m |
| Earnings | €9.41m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 55.63% |
| Net Profit Margin | 2.96% |
| Debt/Equity Ratio | 19.0% |
How did 0RB1 perform over the long term?
See historical performance and comparison